Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis

The diagnostic value and prognostic significance of circulating tumor cell (CTC) detection in patients with bladder cancer is controversial. We performed a meta-analysis to consolidate current evidence regarding the use of CTC detection assays to diagnose bladder and other urothelial cancers and the...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2011-08, Vol.11 (1), p.336-336, Article 336
Main Authors: Msaouel, Pavlos, Koutsilieris, Michael
Format: Article
Language:English
Subjects:
Bladder cancer
Cancer
Cancer cells
Carcinoma, Transitional Cell - blood
Carcinoma, Transitional Cell - diagnosis
Care and treatment
Diagnosis
Epithelial tumors
Humans
Neoplasm Staging
Neoplastic Cells, Circulating - pathology
Physiological aspects
Prognosis
Sensitivity and Specificity
Urinary Bladder Neoplasms - blood
Urinary Bladder Neoplasms - diagnosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The diagnostic value and prognostic significance of circulating tumor cell (CTC) detection in patients with bladder cancer is controversial. We performed a meta-analysis to consolidate current evidence regarding the use of CTC detection assays to diagnose bladder and other urothelial cancers and the association of CTC positivity with advanced, remote disease. Studies that investigated the presence of CTCs in the peripheral blood of patients with bladder cancer and/or urothelial cancer were identified and reviewed. Sensitivities, specificities, and positive (LR+) and negative likelihood ratios (LR-) of CTC detection in individual studies were calculated and meta-analyzed by random effects model. Overall odds ratio of CTC positivity in patients with advanced disease versus those with organ-confined cancer was also calculated. Overall sensitivity of CTC detection assays was 35.1% (95%CI, 32.4-38%); specificity, LR+, and LR- was 89.4% (95%CI, 87.2-91.3%), 3.77 (95%CI, 1.95-7.30) and 0.72 (95%CI, 0.64-0.81). CTC-positive patients were significantly more likely to have advanced (stage III-IV) disease compared with CTC-negative patients (OR, 5.05; 95%CI, 2.49-10.26). CTC evaluation can confirm tumor diagnosis and identify patients with advanced bladder cancer. However, due to the low overall sensitivity, CTC detection assays should not be used as initial screening tests.
ISSN:1471-2407
1471-2407
DOI:10.1186/1471-2407-11-336